HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Srinivasan, M. Articles by Whitacre, C. C. Search for Related Content PubMed PubMed Citation Articles by Srinivasan, M. Articles by Whitacre, C. C.

Suppression of Experimental Autoimmune Encephalomyelitis Using Peptide Mimics of CD28¹

Mythily Srinivasan^*, Ingrid E. Gienapp, Scott S. Stuckman, Connie J. Rogers, Scott D. Jewell, Pravin T. P. Kaumaya^*, and Caroline C. Whitacre^2,

^* Department of Microbiology, College of Biological Sciences, and Departments of Pathology, Obstetrics and Gynecology, and Molecular Virology, Immunology, and Medical Genetics, College of Medicine and Public Health, Ohio State University, Columbus, OH 43210

The B7:CD28/CTLA-4 costimulatory pathway plays a critical role in regulating the immune response and thus provides an ideal target for therapeutic manipulation of autoimmune disease. Previous studies have shown that blockade of CD28 signaling by mAbs can both prevent and exacerbate experimental autoimmune encephalomyelitis (EAE). In this study, we have designed two CD28 peptide mimics that selectively block B7:CD28 interactions. By surface plasmon resonance, both the end group-blocked CD28 peptide (EL-CD28) and its retro-inverso isomer (RI-CD28) compete effectively with the extracellular domain of CD28 for binding to B7-1. Both the CD28 peptide mimics inhibited expansion of encephalitogenic T cells in vitro. A single administration of EL-CD28 or RI-CD28 peptide significantly reduced disease severity in EAE. Importantly, we show that either CD28 peptide mimic administered during acute disease dramatically improved clinical signs of EAE, suppressing ongoing disease. The ratio of CD80:CD86 expression was significantly lower on CD4⁺ and F4/80⁺ spleen cells in CD28 peptide-treated mice. Peripheral deletion of Ag-specific CD4⁺ T cells occurs following in vivo blockade of CD28 with synthetic CD28 peptides.

This article has been cited by other articles:

				N. Kobayashi, H. Kobayashi, L. Gu, T. Malefyt, and T. J. Siahaan Antigen-Specific Suppression of Experimental Autoimmune Encephalomyelitis by a Novel Bifunctional Peptide Inhibitor J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 879 - 886. [Abstract] [Full Text] [PDF]

				J. R. Podojil, A. P. Kohm, and S. D. Miller CD4+ T Cell Expressed CD80 Regulates Central Nervous System Effector Function and Survival during Experimental Autoimmune Encephalomyelitis. J. Immunol., September 1, 2006; 177(5): 2948 - 2958. [Abstract] [Full Text] [PDF]

				M. Srinivasan, D. Lu, R. Eri, D. D. Brand, A. Haque, and J. S. Blum CD80 Binding Polyproline Helical Peptide Inhibits T Cell Activation J. Biol. Chem., March 18, 2005; 280(11): 10149 - 10155. [Abstract] [Full Text] [PDF]